Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.

It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura.

In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases.

Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases.

The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc.

Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.